Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

BACKGROUND: In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelzer, Uwe, Blanc, Jean-Frédéric, Melisi, Davide, Cubillo, Antonio, Von Hoff, Daniel D, Wang-Gillam, Andrea, Chen, Li-Tzong, Siveke, Jens T, Wan, Yin, Solem, Caitlyn T, Botteman, Marc F, Yang, Yoojung, de Jong, Floris A, Hubner, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482729/
https://www.ncbi.nlm.nih.gov/pubmed/28350787
http://dx.doi.org/10.1038/bjc.2017.67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482729/
https://www.ncbi.nlm.nih.gov/pubmed/28350787
http://dx.doi.org/10.1038/bjc.2017.67

Ejemplares similares